Perioperative medicine & outcomes
Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial
Authors' conclusion
Fosaprepitant added to dexamethasone and palonosetron reduced the incidence of PONV in patients at high risk of PONV undergoing laparoscopic gastrointestinal surgery. Notably, it increased the incidence of intraoperative hypotension.
Study context
- Population
- Patients at high risk of postoperative nausea and vomiting (PONV) undergoing laparoscopic gastrointestinal surgery, receiving dexamethasone 5 mg and palonosetron 0.075 mg IV
- Participants
- 1,154 patients
- Comparison
- Fosaprepitant vs Placebo
- Fosaprepitantn = 577
- Placebon = 577reference
- Primary endpoint
- Incidence of PONV (nausea, retching, or vomiting)
- Follow-up
- First 24 postoperative hours
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Each group vs placeboAdjusted risk difference (95% CI)P value
Fosaprepitant
−16.9%(−22.4 to −11.4%)
P < 0.001Each group vs placeboAdjusted relative risk (95% CI)P value
Fosaprepitant
0.65(0.57–0.76)
P < 0.001Safety
Intraoperative hypotension · higher with fosaprepitant
P = 0.026
Intraoperative hypertension · lower with fosaprepitant
P = 0.003
Severe adverse events
- No differences between groups
Original publication
Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial. Br J Anaesth. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →